Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varoglutamstat in early Alzheimer's disease
NCT03919162Phase 2Terminated
- Sponsor
- Vivoryon Therapeutics N.V.
- Start
- Nov 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing PQ912 (Varoglutamstat) with Placebo (2 arms). Primary endpoints: Adverse Events of Special Interest at 16 weeks, Target Occupancy at 24 weeks and 4 more. Started Nov 2021; status: terminated.
02
Drugs
varoglutamstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03919162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919162.